title: Management of hepatocellular carcinoma.
abstract: Hepatocellular carcinoma is the fifth most common cancer in the world and is the third cause of cancer-related death with varying prevalence according to endemic risk factors. Despite therapeutic advances, there has not been significant improvement in the overall survival of patients who have hepatocellular cancer in the last 2 decades. Treatment selection should be based on tumor characteristics and the underlying liver disease.
authors.affiliation: Recanati Miller Transplantation Institute, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1106, New York, NY 10026, USA. ana.delpozo@mountsinai.org
authors.forename: Ana Carolina
authors.initials: AC
authors.lastname: Del Pozo
authors.forename: Patricia
authors.initials: P
authors.lastname: López
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D016031:Liver Transplantation; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents